The Wall Street Journal takes a look at Moderna Inc. – and it isn’t a pretty picture for the Cambridge company that only a few years was hailed as a world hero for developing a COVID-19 vaccine in 2021. Today? It’s been kicked to the curb by Wall Street investors, with its share price plummeting from a high of $484 in 2021 to around $27 today. The main causes: a changing regulatory environment for vaccines (read: RFK Jr.) and a failure to diversify its products.

Update – 6.10.25 – From the Globe: “‘People inside Moderna are afraid’: As the anti-vaccine climate intensifies, a big local firm has much to lose.”